{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:33:47Z","timestamp":1777268027173,"version":"3.51.4"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"22","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Purpose: Classic lobular carcinomas (CLC) account for 10% to 15% of all breast cancers. At the genetic level, CLCs show recurrent physical loss of chromosome16q coupled with the lack of E-cadherin (CDH1 gene) expression. However, little is known about the putative therapeutic targets for these tumors. The aim of this study was to characterize CLCs at the molecular genetic level and identify putative therapeutic targets.<\/jats:p>\n                  <jats:p>Experimental Design: We subjected 13 cases of CLC to a comprehensive molecular analysis including immunohistochemistry for E-cadherin, estrogen and progesterone receptors, HER2\/neu and p53; high-resolution comparative genomic hybridization (HR-CGH); microarray-based CGH (aCGH); and fluorescent and chromogenic in situ hybridization for CCND1 and FGFR1.<\/jats:p>\n                  <jats:p>Results: All cases lacked the expression of E-cadherin, p53, and HER2, and all but one case was positive for estrogen receptors. HR-CGH revealed recurrent gains on 1q and losses on 16q (both, 85%). aCGH showed a good agreement with but higher resolution and sensitivity than HR-CGH. Recurrent, high level gains at 11q13 (CCND1) and 8p12-p11.2 were identified in seven and six cases, respectively, and were validated with in situ hybridization. Examination of aCGH and the gene expression profile data of the cell lines, MDA-MB-134 and ZR-75-1, which harbor distinct gains of 8p12-p11.2, identified FGFR1 as a putative amplicon driver of 8p12-p11.2 amplification in MDA-MB-134. Inhibition of FGFR1 expression using small interfering RNA or a small-molecule chemical inhibitor showed that FGFR1 signaling contributes to the survival of MDA-MB-134 cells.<\/jats:p>\n                  <jats:p>Conclusions: Our findings suggest that receptor FGFR1 inhibitors may be useful as therapeutics in a subset of CLCs.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-06-1164","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T11:48:51Z","timestamp":1164196131000},"page":"6652-6662","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":235,"title":["<i>FGFR1<\/i>\n                    Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas"],"prefix":"10.1158","volume":"12","author":[{"given":"Jorge Sergio","family":"Reis-Filho","sequence":"first","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom;"},{"name":"2IPATIMUP-Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal;"}]},{"given":"Pete T.","family":"Simpson","sequence":"additional","affiliation":[{"name":"3Molecular and Cellular Pathology, Mayne Medical School, University of Queensland, Queensland Institute of Medical Research and Royal Brisbane and Women's Hospital, Brisbane, Australia;"}]},{"given":"Nicholas C.","family":"Turner","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom;"}]},{"given":"Maryou Ballo","family":"Lambros","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom;"}]},{"given":"Chris","family":"Jones","sequence":"additional","affiliation":[{"name":"4Section of Paediatric Oncology, Institute of Cancer Research, Sutton, United Kingdom;"}]},{"given":"Alan","family":"Mackay","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom;"}]},{"given":"Anita","family":"Grigoriadis","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom;"}]},{"given":"David","family":"Sarrio","sequence":"additional","affiliation":[{"name":"6Centro Nacional de Investigaciones Oncolo\u0301gicas, and"}]},{"given":"Kay","family":"Savage","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom;"}]},{"given":"Tim","family":"Dexter","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom;"}]},{"given":"Marjan","family":"Iravani","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom;"}]},{"given":"Kerry","family":"Fenwick","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom;"}]},{"given":"Barbara","family":"Weber","sequence":"additional","affiliation":[{"name":"5University of Pennsylvania, Philadelphia, Pennsylvania; and"}]},{"given":"David","family":"Hardisson","sequence":"additional","affiliation":[{"name":"7Department of Pathology, La Paz Hospital, Madrid, Spain"}]},{"given":"Fernando Carlos","family":"Schmitt","sequence":"additional","affiliation":[{"name":"2IPATIMUP-Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal;"}]},{"given":"Jose","family":"Palacios","sequence":"additional","affiliation":[{"name":"6Centro Nacional de Investigaciones Oncolo\u0301gicas, and"}]},{"given":"Sunil R.","family":"Lakhani","sequence":"additional","affiliation":[{"name":"3Molecular and Cellular Pathology, Mayne Medical School, University of Queensland, Queensland Institute of Medical Research and Royal Brisbane and Women's Hospital, Brisbane, Australia;"}]},{"given":"Alan","family":"Ashworth","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom;"}]}],"member":"1086","published-online":{"date-parts":[[2006,11,22]]},"reference":[{"key":"2022061104590325500_B1","doi-asserted-by":"crossref","unstructured":"Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol\u20082005;205:248\u201354.","DOI":"10.1002\/path.1691"},{"key":"2022061104590325500_B2","doi-asserted-by":"crossref","unstructured":"Reis Filho JS, Simpson PT, Gale T, Lakhani SR. The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. Pathol Res Pract\u20082005;201:713\u201325.","DOI":"10.1016\/j.prp.2005.05.013"},{"key":"2022061104590325500_B3","doi-asserted-by":"crossref","unstructured":"Stange DE, Radlwimmer B, Schubert F, et al. High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin Cancer Res\u20082006;12:345\u201352.","DOI":"10.1158\/1078-0432.CCR-05-1633"},{"key":"2022061104590325500_B4","doi-asserted-by":"crossref","unstructured":"Rakha EA, Green AR, Powe DG, Roylance R, Ellis IO. Chromosome 16 tumor-suppressor genes in breast cancer. Genes Chromosomes Cancer\u20082006;45:527\u201335.","DOI":"10.1002\/gcc.20318"},{"key":"2022061104590325500_B5","doi-asserted-by":"crossref","unstructured":"Berx G, Cleton-Jansen AM, Nollet F, et al. E-cadherin is a tumour\/invasion suppressor gene mutated in human lobular breast cancers. EMBO J\u20081995;14:6107\u201315.","DOI":"10.1002\/j.1460-2075.1995.tb00301.x"},{"key":"2022061104590325500_B6","doi-asserted-by":"crossref","unstructured":"Sarrio D, Moreno-Bueno G, Hardisson D, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer\u20082003;106:208\u201315.","DOI":"10.1002\/ijc.11197"},{"key":"2022061104590325500_B7","doi-asserted-by":"crossref","unstructured":"Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer\u20082001;92:404\u20138.","DOI":"10.1002\/ijc.1208"},{"key":"2022061104590325500_B8","doi-asserted-by":"crossref","unstructured":"Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet\u20082004;41:508\u201317.","DOI":"10.1136\/jmg.2004.018275"},{"key":"2022061104590325500_B9","doi-asserted-by":"crossref","unstructured":"Etzell JE, Devries S, Chew K, et al. Loss of chromosome 16q in lobular carcinoma in situ. Hum Pathol\u20082001;32:292\u20136.","DOI":"10.1053\/hupa.2001.22759"},{"key":"2022061104590325500_B10","doi-asserted-by":"crossref","unstructured":"Nishizaki T, Chew K, Chu L, et al. Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer\u20081997;74:513\u20137.","DOI":"10.1002\/(SICI)1097-0215(19971021)74:5<513::AID-IJC6>3.0.CO;2-6"},{"key":"2022061104590325500_B11","unstructured":"Lu YJ, Osin P, Lakhani SR, Di Palma S, Gusterson BA, Shipley JM. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res\u20081998;58:4721\u20137."},{"key":"2022061104590325500_B12","doi-asserted-by":"crossref","unstructured":"Loo LW, Grove DI, Williams EM, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res\u20082004;64:8541\u20139.","DOI":"10.1158\/0008-5472.CAN-04-1992"},{"key":"2022061104590325500_B13","doi-asserted-by":"crossref","unstructured":"Shelley-Hwang E, Nyante SJ, Yi Chen Y, et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer\u20082004;100:2562\u201372.","DOI":"10.1002\/cncr.20273"},{"key":"2022061104590325500_B14","doi-asserted-by":"crossref","unstructured":"Hoff ER, Tubbs RR, Myles JL, Procop GW. HER2\/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol\u20082002;117:916\u201321.","DOI":"10.1309\/4NTU-N6K4-F8JF-EWRX"},{"key":"2022061104590325500_B15","doi-asserted-by":"crossref","unstructured":"Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res\u20082004;6:R149\u201356.","DOI":"10.1186\/bcr767"},{"key":"2022061104590325500_B16","unstructured":"Courjal F, Cuny M, Simony-Lafontaine J, et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res\u20081997;57:4360\u20137."},{"key":"2022061104590325500_B17","unstructured":"Oyama T, Kashiwabara K, Yoshimoto K, Arnold A, Koerner F. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res\u20081998;58:2876\u201380."},{"key":"2022061104590325500_B18","doi-asserted-by":"crossref","unstructured":"Smith DB, Howell A, Wagstaff J. Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival. Eur J Cancer Clin Oncol\u20081987;23:979\u201382.","DOI":"10.1016\/0277-5379(87)90344-0"},{"key":"2022061104590325500_B19","doi-asserted-by":"crossref","unstructured":"Cocquyt VF, Blondeel PN, Depypere HT, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol\u20082003;29:361\u20137.","DOI":"10.1053\/ejso.2002.1404"},{"key":"2022061104590325500_B20","doi-asserted-by":"crossref","unstructured":"Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol\u20082005;23:41\u20138.","DOI":"10.1200\/JCO.2005.03.111"},{"key":"2022061104590325500_B21","doi-asserted-by":"crossref","unstructured":"Reis-Filho JS, Simpson PT, Jones C, et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol\u20082005;207:1\u201313.","DOI":"10.1002\/path.1806"},{"key":"2022061104590325500_B22","doi-asserted-by":"crossref","unstructured":"Lambros MBK, Simpson PT, Jones C, et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridisation. Lab Invest\u20082006;86:398\u2013408.","DOI":"10.1038\/labinvest.3700390"},{"key":"2022061104590325500_B23","doi-asserted-by":"crossref","unstructured":"Mohammadi M, McMahon G, Sun L, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science\u20081997;276:955\u201360.","DOI":"10.1126\/science.276.5314.955"},{"key":"2022061104590325500_B24","doi-asserted-by":"crossref","unstructured":"Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat Genet\u20082004;36:949\u201351.","DOI":"10.1038\/ng1416"},{"key":"2022061104590325500_B25","doi-asserted-by":"crossref","unstructured":"Sharp AJ, Locke DP, McGrath SD, et al. Segmental duplications and copy-number variation in the human genome. Am J Hum Genet\u20082005;77:78\u201388.","DOI":"10.1086\/431652"},{"key":"2022061104590325500_B26","doi-asserted-by":"crossref","unstructured":"Pole JC, Courtay-Cahen C, Garcia MJ, et al. High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation. Oncogene 2006: Epub ahead of print [doi: 10.1038\/sj.onc.1209570].","DOI":"10.1038\/sj.onc.1209570"},{"key":"2022061104590325500_B27","doi-asserted-by":"crossref","unstructured":"Coquelle A, Pipiras E, Toledo F, Buttin G, Debatisse M. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell\u20081997;89:215\u201325.","DOI":"10.1016\/S0092-8674(00)80201-9"},{"key":"2022061104590325500_B28","doi-asserted-by":"crossref","unstructured":"Gelsi-Boyer V, Orsetti B, Cervera N, et al. Comprehensive profiling of 8p11\u201312 amplification in breast cancer. Mol Cancer Res\u20082005;3:655\u201367.","DOI":"10.1158\/1541-7786.MCR-05-0128"},{"key":"2022061104590325500_B29","doi-asserted-by":"crossref","unstructured":"Adelaide J, Huang HE, Murati A, et al. A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin\/NRG1 gene. Genes Chromosomes Cancer\u20082003;37:333\u201345.","DOI":"10.1002\/gcc.10218"},{"key":"2022061104590325500_B30","unstructured":"Dib A, Adelaide J, Chaffanet M, et al. Characterization of the region of the short arm of chromosome 8 amplified in breast carcinoma. Oncogene\u20081995;10:995\u20131001."},{"key":"2022061104590325500_B31","doi-asserted-by":"crossref","unstructured":"Luqmani YA, Graham M, Coombes RC. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer\u20081992;66:273\u201380.","DOI":"10.1038\/bjc.1992.256"},{"key":"2022061104590325500_B32","doi-asserted-by":"crossref","unstructured":"Jacquemier J, Adelaide J, Parc P, et al. Expression of the FGFR1 gene in human breast-carcinoma cells. Int J Cancer\u20081994;59:373\u20138.","DOI":"10.1002\/ijc.2910590314"},{"key":"2022061104590325500_B33","doi-asserted-by":"crossref","unstructured":"Ugolini F, Adelaide J, Charafe-Jauffret E, et al. Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1\/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes. Oncogene\u20081999;18:1903\u201310.","DOI":"10.1038\/sj.onc.1202739"},{"key":"2022061104590325500_B34","unstructured":"Cuny M, Kramar A, Courjal F, et al. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res\u20082000;60:1077\u201383."},{"key":"2022061104590325500_B35","doi-asserted-by":"crossref","unstructured":"Prentice LM, Shadeo A, Lestou VS, et al. NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene\u20082005;24:7281\u20139.","DOI":"10.1038\/sj.onc.1208892"},{"key":"2022061104590325500_B36","doi-asserted-by":"crossref","unstructured":"Still IH, Hamilton M, Vince P, Wolfman A, Cowell JK. Cloning of TACC1, an embryonically expressed, potentially transforming coiled coil containing gene, from the 8p11 breast cancer amplicon. Oncogene\u20081999;18:4032\u20138.","DOI":"10.1038\/sj.onc.1202801"},{"key":"2022061104590325500_B37","unstructured":"Cleator S, Tsimelzon A, Ashworth A, et al. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Res Treat\u20082005;37:1\u20135."},{"key":"2022061104590325500_B38","doi-asserted-by":"crossref","unstructured":"Tsuda H, Takarabe T, Hirohashi S. Correlation of numerical and structural status of chromosome 16 with histological type and grade of non-invasive and invasive breast carcinomas. Int J Cancer\u20081999;84:381\u20137.","DOI":"10.1002\/(SICI)1097-0215(19990820)84:4<381::AID-IJC9>3.0.CO;2-Y"},{"key":"2022061104590325500_B39","doi-asserted-by":"crossref","unstructured":"Flagiello D, Gerbault-Seureau M, Sastre-Garau X, Padoy E, Vielh P, Dutrillaux B. Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer. Genes Chromosomes Cancer\u20081998;23:300\u20136.","DOI":"10.1002\/(SICI)1098-2264(199812)23:4<300::AID-GCC4>3.0.CO;2-N"},{"key":"2022061104590325500_B40","unstructured":"Iravani M, Fenwick K, Grigoriadis A, et al. Integrated molecular profiling of human breast cell types and breast cancer cell lines using expression microarrays and array CGH [abstract]. Breast Cancer Res Treat\u20082005;94:S27."},{"key":"2022061104590325500_B41","doi-asserted-by":"crossref","unstructured":"Davidson JM, Gorringe KL, Chin SF, et al. Molecular cytogenetic analysis of breast cancer cell lines. Br J Cancer\u20082000;83:1309\u201317.","DOI":"10.1054\/bjoc.2000.1458"},{"key":"2022061104590325500_B42","doi-asserted-by":"crossref","unstructured":"Bautista S, Theillet C. CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei. Genes Chromosomes Cancer\u20081998;22:268\u201377.","DOI":"10.1002\/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T"},{"key":"2022061104590325500_B43","unstructured":"Hiraguri S, Godfrey T, Nakamura H, et al. Mechanisms of inactivation of E-cadherin in breast cancer cell lines. Cancer Res\u20081998;58:1972\u20137."},{"key":"2022061104590325500_B44","doi-asserted-by":"crossref","unstructured":"Warri AM, Laine AM, Majasuo KE, Alitalo KK, Harkonen PL. Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. Int J Cancer\u20081991;49:616\u201323.","DOI":"10.1002\/ijc.2910490425"},{"key":"2022061104590325500_B45","doi-asserted-by":"crossref","unstructured":"Garcia MJ, Pole JC, Chin SF, et al. A 1 Mb minimal amplicon at 8p11\u201312 in breast cancer identifies new candidate oncogenes. Oncogene\u20082005;24:5235\u201345.","DOI":"10.1038\/sj.onc.1208741"},{"key":"2022061104590325500_B46","doi-asserted-by":"crossref","unstructured":"Huang HE, Chin SF, Ginestier C, et al. A recurrent chromosome breakpoint in breast cancer at the NRG1\/neuregulin 1\/heregulin gene. Cancer Res\u20082004;64:6840\u20134.","DOI":"10.1158\/0008-5472.CAN-04-1762"},{"key":"2022061104590325500_B47","doi-asserted-by":"crossref","unstructured":"Al-Kuraya K, Schraml P, Torhorst J, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res\u20082004;64:8534\u201340.","DOI":"10.1158\/0008-5472.CAN-04-1945"},{"key":"2022061104590325500_B48","doi-asserted-by":"crossref","unstructured":"Xian W, Schwertfeger KL, Vargo-Gogola T, Rosen JM. Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol\u20082005;171:663\u201373.","DOI":"10.1083\/jcb.200505098"},{"key":"2022061104590325500_B49","doi-asserted-by":"crossref","unstructured":"Ray ME, Yang ZQ, Albertson D, et al. Genomic and expression analysis of the 8p11\u201312 amplicon in human breast cancer cell lines. Cancer Res\u20082004;64:40\u20137.","DOI":"10.1158\/0008-5472.CAN-03-1022"},{"key":"2022061104590325500_B50","doi-asserted-by":"crossref","unstructured":"Yang ZQ, Albertson D, Ethier SP. Genomic organization of the 8p11\u201312 amplicon in three breast cancer cell lines. Cancer Genet Cytogenet\u20082004;155:57\u201362.","DOI":"10.1016\/j.cancergencyto.2004.03.013"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/12\/22\/6652\/1922163\/6652.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/12\/22\/6652\/1922163\/6652.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T15:34:31Z","timestamp":1654961671000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/12\/22\/6652\/191472\/FGFR1-Emerges-as-a-Potential-Therapeutic-Target"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,15]]},"references-count":50,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2006,11,22]]},"published-print":{"date-parts":[[2006,11,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-06-1164","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.22441986","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22441983.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6518832","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22441986.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22441983","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6518832.v1","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,15]]}}}